Modafinil in the treatment of excessive daytime sleepiness in children

Abstract: Modafinil for children

Background:

 Modafinil is an alerting agent approved for the treatment of narcolepsy in adults. There are no studies examining the long-term effects and safety profile of modafinil in children with excessive daytime somnolence (EDS). 

Objectives:

To determine the effects of modafinil on clinical manifestations of narcolepsy and idiopathic hypersomnia.

Methods:

A systematic chart review was conducted for 13 children (mean age 11.0+/-5.3 years, six males, 10 with narcolepsy and three with idiopathic hypersomnia) receiving modafinil.

Results:

The mean modafinil dose was 346+/-119 mg/day, with a mean treatment duration of 15.6+/-7.8 months. For approximately 90% of the children treated, parents reported a favorable response with the reduction in sudden sleep attacks, as documented by sleep-wake diaries. One child failed to improve on 400 mg/day modafinil and was switched to methylphenidate. Two other children showed only partial improvement and required additional stimulant medication to control EDS symptoms. Seven children underwent repeated nocturnal polysomnography and multiple sleep latency tests (MSLT). Compared to baseline MSLT measures (mean sleep latency: 6.6+/-3.7 min), modafinil prolonged mean sleep latency (10.2+/-4.8 min, p=0.02) without significant alteration in nocturnal polysomnographic measures. However, a trend towards REM sleep reduction was noted (16.8+/-5.1%TST vs. 11.8+/-6.2%TST). Exacerbation of seizures and psychotic symptoms was reported with modafinil therapy in two children with preexisting conditions. Hematological and hepatic functions assessed every 3 months remained unaltered.

Conclusion:

Modafinil has a modest, yet significant effect on EDS in children and appears to be safe and well tolerated.

Works Cited

1. Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Muzaffer Kaser, Julia B Deakin , Albert Michael , Camilo Zapata , Rachna Bansal , Dragana Ryan , Francesca Cormack , James B Rowe , Barbara J Sahakian.

2. Cognitive enhancing effects of modafinil in healthy volunteers. Danielle C. Turner, Trevor W. Robbins, Luke Clark, Adam R. Aron, Jonathan Dowson & Barbara J. Sahakian.

3. Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species. Zackary A.Cope, Arpi Minassian, DustinKreitner, David A. MacQueen, MorganeMilienne-Petiot, Mark A.Geyer, WilliamPerry, Jared W.Young.

4. Effects of modafinil on cognitive performance and alertness during sleep deprivation. Wesensten, Nancy J.

5. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas. Pascal Jean-Pierre 1, Gary R Morrow, Joseph A Roscoe, Charles Heckler, Supriya Mohile, Michelle Janelsins, Luke Peppone, Amy Hemstad, Benjamin T Esparaz, Judith O Hopkins.

6. Modafinil. Karl Greenblatt, Ninos Adams.

7. Modafinil reduces depression’s severity when taken with antidepressants. Barbara Sahakian, Dr Muzaffer Kaser.

8. Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study. Terence A.Ketter, JessAmchin, Mark A.Frye, NicholasGross.

9. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study. LeslieLundt.

10. Modafinil and Memory: Effects of Modafinil on Morris Water Maze Learning and Pavlovian Fear Conditioning. Tristan Shuman, Suzanne C. Wood, and Stephan G. Anagnostaras.

11. wikipedia.

12. School of Health Sciences. Wharrad, Heather.

13. FDA basics.

14. United States Drug Enforcement Administration.

15. Drug Scheduling. DEA.

16. Is modafinil safe in the long term? Cox, David.

17. Modafinil treatment for fatigue in HIV+ patients: a pilot study. Judith G Rabkin 1, Martin C McElhiney, Richard Rabkin, Stephen J Ferrando.

18. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study. Samuel W Boellner, Craig Q Earl, Sanjay Arora.

19. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. Joseph Biederman, Steven R Pliszka.

20. Modafinil in the treatment of excessive daytime sleepiness in children. Gozal, Anna Ivanenko Riva Tauman David.

Listen to the podcast of this blog :